Qi Gong as a Method of Craving Reduction in Severe Addict Patients
QICA
2 other identifiers
interventional
186
1 country
3
Brief Summary
Craving arises in response to an affective tone that is associated with perceptual representations of a sensory object, rather than directly in response to the object. The investigators presume that qi gong functions to decouple pleasant and unpleasant experience from habitual reactions by removing the affective bias that fuels such emotional reactivity. Qi gong training may specifically target the associated learning process with an emphasis on the critical link between affect and craving in an addictive loop.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2018
Typical duration for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 18, 2018
CompletedFirst Posted
Study publicly available on registry
July 17, 2018
CompletedStudy Start
First participant enrolled
October 4, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedJuly 17, 2019
July 1, 2019
2.2 years
May 18, 2018
July 15, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Variation of craving intensity
Variation of craving intensity on a Vvisual aAnalogic sScale (VAS) between baseline and the end of the treatment. The intensity is measured by "not at all" (score of 0) and "craving as bad as it could be" or "the most I've ever felt " (maximum score of 10), self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents his craving intensity. The score is determined by measuring the distance on the 10-cm line between the "no craving" anchor and the patient's mark.
Change in VAS from baseline to 9 weeks treatment
Secondary Outcomes (9)
Evolution over time of craving intensity
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Difference in treatment retention
3 weeks and 9 weeks post-baseline
Evolution over time of total alcohol consumption
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Evoluation over time of anxiety
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Evolution over time of depression
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
- +4 more secondary outcomes
Study Arms (2)
Qi Gong
EXPERIMENTALQi gong sessions added to usual well defined medical and psychological support
Control
NO INTERVENTIONUsual well defined medical and psychological support
Interventions
Eligibility Criteria
You may qualify if:
- Meets DSM 5 criteria for alcohol use disorder and other substance use disorders
- Alcohol is one of the major abused substances if using multiple substances
- Severity of the disorder defines by the necessity of a complex withdrawal hospitalization.
- Used alcohol in the 3 weeks before hospitalization
- Seeks addiction treatment
- Patient willing to adhere to the study protocol (e.g. attend all visits and follow-ups in the next 3 months).
- Age ≥ 18
- Negative pregnancy test (βHCG) for women of child bearing potential
- Signed informed consent
- Affiliation to the French health insurance (recipient or assign)
- Oral and written comprehension of the french langage
- Pose a current suicidal risk including active suicidal ideation and suicide attempt in the past 30 days
- Non stabilized severe psychiatric comorbidities such as bipolar disorder, schizophrenia, … (at the investigator's discretion)
- Pregnant or breastfeeding women
- Decompensated cirrhosis, liver encephalopathy, neurological complications, severe cognitive impairment and any other severe somatic comorbidity (at the investigator's discretion)
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Hôpital Saint ELOI
Montpellier, 34000, France
Hôpital L'ARCHET
Nice, 06002, France
Groupe Hospitalier Pitié Salpêtrière
Paris, 75013, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alain BAUMELOU, MD, Ph.D
Assistance Publique - Hôpitaux de Paris
- STUDY DIRECTOR
Nathalie PLET, Ph.D
Assistance Publique - Hôpitaux de Paris
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Primary outcome (VAS scale) will be presented to the patient and reported by a study nurse blinded of the randomization arm of the patient.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 18, 2018
First Posted
July 17, 2018
Study Start
October 4, 2018
Primary Completion
December 1, 2020
Study Completion
December 1, 2020
Last Updated
July 17, 2019
Record last verified: 2019-07